Linda Stocum, Associate Editor

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis.

Vivace microneedling device receives FDA clearance on 2MHz radiofrequency setting.

New TrichoTest aims to help clinicians diagnose and treat alopecia.

In the first part of our 3-part recap series of our Roadmap to Recovery webinar, panelists discussed how the dermatology practice changed during COVID-19 and what changes they plan on keeping.

Hugel America announces the FDA has approved the BLA application for letibotulinumtoxinA as a treatment for glabellar lines in adult patients.

Nutrafol launches a new nutraceutical, called Postpartum, aimed at helping women’s hair health post-pregnancy.

IDP-126, an acne vulgaris treatment for patients ages 9 and older, met all of its endpoints in a 12-week phase 3 study.

The B-SIMPLE4 phase 3 trial achieved positive efficacy results for the treatment of molluscum contagiosum.

Emmy Graber, MD, presented the updates in acne and rosacea treatments at the SCALE Acne and Rosacea update on June 9, 2021.

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

The Journal of the American Academy of Dermatology has published new recommendations for the treatment of actinic keratosis (AK).

Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.

The SaltFacial achieves promising results in treating multiple skin conditions.

A new FDA-approved eyedrop offers patients a nonsurgical option for eyelid lifts.

Content-aware image restoration (CARE) technology demonstrated improvement in examining cellular details of skin.

A study examined the difference in prescribing patterns between pediatricians and dermatologists when it came to acne treatments.

A cohort study investigated the association between MHT and acne diagnosis.

Research analyses found an increased risk of cSCC after AK diagnosis during long periods of follow up.

A new study shows a possible association between fasting and skin improvement in psoriasis patients.

A study published in JAMA Dermatology investigated how consumers look at sunscreen active ingredients in response to an FDA proposed rule.

Psoriasis patients may have a higher risk of contracting COVID-19, according to study results recently presented at AAD VMX 2021.

New study data presented at EADV demonstrated an association between COVID-19 severity in male patients and the sex hormone androgen.

Research presented at the EADV Spring Symposium 2021 investigated the link between gut bacteria and skin inflammation.

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events.

After data from a phase 3 study, FDA opens potential for apremilast to be the first and only approved oral therapy for mild to moderate plaque psoriasis.

New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).

A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.

According to study data recently presented at AAD VMX 2021, tofacitinib demonstrated positive results when being evaluated as a possible treatment for cutaneous sarcoidosis.

Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.

A phase 3 trial produced results on the efficacy of different doses of the JAK1 inhibitor.